CT-388 vs Mazdutide

What the evidence actually compares

CT-388 (enicepatide; RO7795068) is an investigational peptide activating GLP-1 and GIP receptors with signaling bias. Mazdutide activates GLP-1 and glucagon receptors. The receptor pair is therefore different.

A published report combines preclinical experiments with a randomized phase 1 trial (NCT04838405) in otherwise healthy adults with overweight or obesity, including single-dose and four-week repeated-dose cohorts. Longer-duration weight figures publicized by the sponsor should not be presented as peer-reviewed phase 3 outcomes. CT-388 phase 1, PMID 41319798

Mazdutide is a GLP-1/glucagon receptor dual agonist. Its published GLORY-1 and GLORY-2 weight trials enrolled Chinese adults; GLORY-2 included some adults with type 2 diabetes, whereas the separate US phase 2 trial enrolled adults without it. The trials used different follow-up and analysis methods. GLORY-1 · GLORY-2 · US phase 2

Innovent reports Chinese NMPA approvals for specified adult weight-management and type 2 diabetes uses. The reviewed source is a sponsor exchange filing, not an independently retrieved Chinese label. No US FDA mazdutide approval was verified; an FDA letter identifies one US seller’s mazdutide products as unapproved new drugs.

What cannot be inferred

The cited CT-388 clinical exposure is early and short; the published mazdutide GLORY weight trials have longer phase 3 follow-up. Neither study set makes a direct comparative efficacy or long-term safety estimate between the molecules.

CT-388 remained investigational in the reviewed sources; no FDA approval for it or mazdutide was verified. Mazdutide’s specified China approvals are sponsor-reported. The source for the CT-388 evidence above is this primary record; regulatory claims about mazdutide are supported by the linked sponsor filing and FDA letter. No combination-use claim follows from these separate studies.

This comparison is educational research context, not medical advice or a treatment protocol.